HOMA-IR Blood Test: Normal Ranges & Causes | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

HOMA-IR blood test

Homeostatic model assessment of insulin resistance. Also called: HOMA, HOMA1-IR, Homeostasis model assessment

Biomarker guideLast updated: November 2, 2026

HOMA-IR estimates insulin resistance from one fasting blood draw: fasting insulin × fasting glucose ÷ 22.5 (÷ 405 in US glucose units). Higher means more insulin resistance. No lab or guideline sets a cut-off; studies put it at about 1.85 to 2.6.

LOINC 47214-2Hormones

At a glance

What it measuresAn estimate of insulin resistance from fasting insulin and fasting glucose taken at the same time.
FormulaFasting insulin (µIU/mL) × fasting glucose (mmol/L) ÷ 22.5; with glucose in mg/dL, divide by 405.
Cut-offsNo lab or guideline cut-off. Studies: about 2.6 (75th percentile, Spain 2003); 1.85 in non-diabetic men and 2.05 by metabolic-syndrome risk (Spain 2013).
Peptides that move itLowered by Tirzepatide, Retatrutide, Semaglutide and Survodutide in trials; no data for the growth hormone-releasing peptides.
Lab codeLOINC 47214-2; no lab reports it directly (order Labcorp 004333 or Quest 561 insulin with fasting glucose)

What is HOMA-IR?

HOMA-IR (homeostatic model assessment of insulin resistance) turns a fasting insulin and a fasting glucose into one number. It comes from a model of the feedback loop between glucose and insulin, and it correlated well with the euglycaemic clamp, the reference method (Rs = 0.88). The higher the number, the more insulin the body needs to keep fasting glucose normal.

Sources: [1] [2]

How it is made and regulated

Where it is made

HOMA-IR is not made by the body: it is calculated. Matthews and colleagues built a model of how fasting glucose and insulin settle into balance, and compared a person's fasting values with the model to estimate insulin resistance.

Sources: [1]

What controls it

Anything that raises insulin resistance raises HOMA-IR: the pancreas releases more insulin to hold glucose steady, and the product of the two rises. Insulin resistance is present in most people with impaired glucose tolerance or type 2 diabetes and in about 25% of non-obese people with normal glucose tolerance.

Sources: [3] [1]

How it travels in the blood

The original 1985 model came with an approximate formula, which is what most labs and studies use; a computer version (HOMA2) exists but is used less. HOMA needs only a single fasting sample for insulin and glucose.

Sources: [2]

How long it lasts

HOMA-IR moves with fasting insulin and glucose. On treatment it can change within weeks: liraglutide improved it after 2 weeks, before any weight loss.

Sources: [4]

What it does

The estimate is imprecise for one person: its coefficient of variation is 31% for insulin resistance. Its developers recommend it mainly for cohort and population studies.

Sources: [1] [2]

Reference ranges

No lab prints a HOMA-IR range and no guideline sets one. Cut-offs come from population studies and depend on the population, age and sex.

Gayoso-Diz 2013 (2459 adults, Spain)

Peer-reviewed reference study (not a commercial lab). Method: Cut-off from a published population study, not a lab reference interval. Study on PubMed (retrieved November 2, 2026).

GroupRange (score)
90th percentile of the population3.46
Cut-off by metabolic-syndrome components2.05
Non-diabetic men1.85

The authors note the threshold must be adjusted for age in non-diabetic women.

Ascaso 2003 (65 adults with normal glucose)

Peer-reviewed reference study (not a commercial lab). Method: Cut-off from a published population study, not a lab reference interval. Study on PubMed (retrieved November 2, 2026).

GroupRange (score)
75th percentile, used as the insulin-resistance cut-off2.6

Validated against an intravenous glucose tolerance test in adults with normal glucose metabolism.

These are study cut-offs from Spanish adults, not reference intervals; the threshold changes with age in women.

Units: HOMA-IR has no unit. It is fasting insulin (µIU/mL) × fasting glucose (mmol/L) ÷ 22.5, or × fasting glucose (mg/dL) ÷ 405 with US glucose units. [5]

Sources: [5] [6]

Is there an "optimal" range?

There is no agreed HOMA-IR cut-off; published thresholds differ by method and population.

About 2.6

2.6 (75th percentile)

Ascaso 2003

The 75th percentile in adults with normal glucose metabolism, validated against a glucose tolerance test.

Sources: [6]

Lower, by metabolic risk

1.85 to 2.05

Gayoso-Diz 2013

Using metabolic-syndrome components instead of a percentile lowers the cut-off from 3.46 to 2.05, and to 1.85 in non-diabetic men.

Sources: [5]

Not for single results

Population use

Wallace 2004 (HOMA developers)

HOMA is best suited to cohort and epidemiological studies; one result is imprecise.

Sources: [2] [1]

What raises it

FactorHowHow much
Insulin resistance (obesity, impaired glucose tolerance, type 2 diabetes)ConditionHigher fasting insulin is needed to hold glucose steady.No published magnitude [3]
Growth hormone therapyHormoneGrowth hormone raised HOMA in adults with growth hormone deficiency.Up to 2.7-fold at day 5 [7]

What lowers it

FactorHowHow much
Weight loss on incretin drugsPeptideTirzepatide, Retatrutide and Semaglutide lowered HOMA-IR in trials, mostly through weight loss.-51.2% vs -6.2% on placebo (tirzepatide, 52 weeks) [8] [9] [10]
IGF-1PeptideRecombinant IGF-1 (Insulin-Like Growth Factor 1) lowered HOMA in a short study, the opposite of growth hormone.0.66 of baseline by day 2 [7]

Peptides that affect HOMA-IR

How each peptide in our library changes HOMA-IR, from published trials. No FDA label reports HOMA-IR, so every row is a study; some report HOMA2-IR, the updated computer model, which is noted where it applies. No study has reported HOMA-IR after dosing Tesamorelin, CJC-1295, Ipamorelin, Sermorelin, Mod GRF 1-29, Hexarelin, GHRP-2, GHRP-6, MK-677 (Ibutamoren), MOTS-c, 5-Amino-1MQ or Lixisenatide on its own; PubMed searches for each with HOMA find no human dosing data (MOTS-c studies measure the body's own MOTS-c, and the GHRP-6 papers are rodent studies).

PeptideEffect on HOMA-IRSize of effectEvidence
ExenatideLowersNo figure in the abstract: in 174 adults with type 2 diabetes on metformin, adding exenatide 10 micrograms twice daily for 12 months lowered HOMA-IR more than adding placeboA year-long placebo-controlled trial found a greater HOMA-IR fall. [11]Human trials
IGF-1 (Insulin-Like Growth Factor 1)Lowers6 adults with growth hormone deficiency (crossover): HOMA fell to 0.66 of baseline by day 2 of a recombinant IGF-1 infusion, while growth hormone raised it up to 2.7-foldIGF-1 lowered HOMA, the opposite of growth hormone, in a small study. [7]Human trials
LiraglutideLowersNo figure in an open source: in a 14-week randomized trial in adults with obesity and prediabetes, liraglutide improved HOMA-IR and HOMA2 after 2 weeks, before any weight lossImproved HOMA-IR within 2 weeks, ahead of weight loss. [4]Human trials
RetatrutideLowersPhase 2 substudy, 98 adults with obesity and liver fat of 10% or more, 48 weeks: HOMA2-IR -36.3% on 1 mg (not significant), -49.4% on 4 mg, -52.4% on 8 mg and -69.3% on 12 mg vs -11.1% on placeboThe largest HOMA2-IR falls of any peptide here, in one phase 2 substudy. [9]Human trials
SemaglutideLowers2.4 mg, 68 weeks, adults with obesity and prediabetes: HOMA-IR 28% lower than placebo (STEP 1) and 29.7% lower (STEP 3). Adolescents with obesity: -35.0% vs -5.3% on placeboCut HOMA-IR by about a quarter to a third vs placebo in people with prediabetes or obesity. [10] [12]Human trials
SurvodutideLowersNo figure in the abstract: in two phase 2 trials (type 2 diabetes for 16 weeks; overweight or obesity), survodutide lowered HOMA-IR significantly vs placeboLower HOMA-IR in both trials, largely tracking weight loss. [13]Human trials
TirzepatideLowersAdults with obesity and sleep apnea, 10 or 15 mg, 52 weeks: HOMA-IR -51.2% vs -6.2% on placebo without PAP therapy and -55.8% vs -2.7% with PAP. In type 2 diabetes (40 weeks), HOMA2-IR fell 15.5%-24.0% vs 5.1% on semaglutide 1 mgRoughly halved HOMA-IR in placebo-controlled trials; most, but not all, of the fall tracks weight loss. [8] [14]Human trials
DulaglutideNo clear effectMeasured, no clear change: 12-week open-label pilot in type 2 diabetes, HOMA-IR -0.19 on dulaglutide vs -1.71 on empagliflozin; only empagliflozin reduced it significantlyNo significant HOMA-IR change in one small pilot; dulaglutide improved beta-cell function instead. [15]Human trials

What high or low results can mean

A high result

A HOMA-IR above about 2 to 2.6 suggests insulin resistance in adult studies. It means the body needs more insulin than usual to keep fasting glucose normal.

  • Obesity
  • Impaired glucose tolerance or type 2 diabetes
  • Growth hormone excess or therapy

Next step: Read it with fasting glucose, fasting insulin and HbA1c, and discuss it with a clinician.

Sources: [6] [5] [3] [7]

A low result

A low HOMA-IR means good insulin sensitivity. With high glucose and low insulin, it can instead reflect too little insulin production.

  • Good insulin sensitivity
  • Low insulin production

Next step: No action is needed for a low HOMA-IR with normal glucose.

Sources: [1] [16]

How the test works

SampleSerum for insulin and plasma or serum for glucose, drawn at the same fasting visit.
FastingBoth values must be fasting; Labcorp and Quest require a fasting sample for insulin.
TimingNo guideline recommends routine HOMA-IR testing; the ADA diagnoses diabetes with glucose and A1C.
Lab differencesHOMA-IR depends on the insulin assay, and insulin results differ between platforms, so values from different labs are not interchangeable.
RetestingCompare results calculated from the same lab, and read changes against the 31% imprecision of a single estimate.
Labcorp order code004333: Insulin (with fasting glucose, for HOMA-IR)
Quest Diagnostics order code561: Insulin (with fasting glucose, for HOMA-IR)
LOINC codes
  • 47214-2: Homeostasis model assessment
  • 92845-7: Insulin resistance score in Serum by Calculated.CardioIQ (Quest's Cardio IQ insulin resistance score, a different calculation)
  • 62255-5: Lipoprotein insulin resistance score in Serum or Plasma (LP-IR, a 0-100 score from lipoprotein particles, not HOMA)
LOINC 47214-2 on loinc.org

Sources: [17] [18] [16] [19] [1]

History

HOMA turned a single fasting blood draw into an estimate of insulin resistance.

  1. 1985Matthews and colleagues publish the homeostasis model assessment and its approximate formula. [1]
  2. 2004The HOMA developers review its use and abuse and recommend it mainly for cohort and population studies. [2]
  3. 2013A study of 2459 Spanish adults shows HOMA-IR cut-offs shift with metabolic risk, age and sex. [5]

FAQ

How do I calculate HOMA-IR?

Multiply fasting insulin (µIU/mL) by fasting glucose (mmol/L) and divide by 22.5. With glucose in mg/dL, divide by 405 instead.

Sources: [5] [15]

What is a normal HOMA-IR?

There is no lab or guideline range. Studies put the insulin-resistance cut-off at about 2.6 (75th percentile) or 1.85 to 2.05 by metabolic risk.

Sources: [6] [5]

Can I order a HOMA-IR test?

Not as a single test at Labcorp or Quest. Order fasting insulin with fasting glucose and calculate it.

Sources: [17] [18]

Is HOMA-IR accurate?

It correlates well with the clamp reference method (Rs = 0.88), but one result has a 31% coefficient of variation, so small changes are not meaningful.

Sources: [1]

What is the difference between HOMA-IR and HOMA2-IR?

HOMA-IR uses the original 1985 approximate formula; HOMA2 is the updated computer model. Some trials report one, some the other, so their numbers are not directly comparable.

Sources: [2] [9]

Does the ADA use HOMA-IR?

No. The ADA diagnoses diabetes and prediabetes with glucose and A1C.

Sources: [16]

Does tirzepatide affect HOMA-IR?

Yes. In adults with obesity and sleep apnea, HOMA-IR fell 51.2% vs 6.2% on placebo over 52 weeks; in type 2 diabetes, HOMA2-IR fell 15.5%-24.0%.

Sources: [8] [14]

Which peptides lower insulin resistance?

In trials, Tirzepatide, Retatrutide, Semaglutide, Survodutide, Liraglutide and Exenatide lowered HOMA-IR. Retatrutide 12 mg lowered HOMA2-IR 69.3% in a phase 2 substudy.

Sources: [8] [9] [10] [13] [4] [11]

Do growth hormone peptides raise HOMA-IR?

There are no HOMA-IR studies of Tesamorelin, CJC-1295, Ipamorelin or MK-677 (Ibutamoren). Growth hormone itself raised HOMA up to 2.7-fold, while IGF-1 (Insulin-Like Growth Factor 1) lowered it.

Sources: [7]

What other insulin-resistance scores exist?

Labcorp's NMR LipoProfile reports LP-IR, a 0-100 score built from lipoprotein particles. It is a different calculation from HOMA-IR.

Sources: [20]

References

  1. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-9. PMID 3899825
  2. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487-95. PMID 15161807
  3. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-607. PMID 3056758
  4. Mashayekhi M, Nian H, Mayfield D, et al. Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes. Diabetes. 2024;73(1):38-50. PMID 37874653
  5. Gayoso-Diz P, Otero-González A, Rodriguez-Alvarez MX, et al. Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study. BMC Endocr Disord. 2013;13:47. PMID 24131857
  6. Ascaso JF, Pardo S, Real JT, et al. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care. 2003;26(12):3320-5. PMID 14633821
  7. Schmid C, Bianda T, Zwimpfer C, et al. Changes in insulin sensitivity induced by short-term growth hormone (GH) and insulin-like growth factor I (IGF-I) treatment in GH-deficient adults are not associated with changes in adiponectin levels. Growth Horm IGF Res. 2005;15(4):300-3. PMID 16054413
  8. Malhotra A, Grunstein R, Azarbarzin A, et al. Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial. Nat Med. 2026;32(2):653-659. PMID 41540105
  9. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. PMID 38858523
  10. Perreault L, Davies M, Frias JP, et al. Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program. Diabetes Care. 2022;45(10):2396-2405. PMID 35724304
  11. Derosa G, Franzetti IG, Querci F, et al. Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes. Diabet Med. 2012;29(12):1515-23. PMID 22540883
  12. Arslanian S, Gies I, Goldman B, et al. Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study. Diabetes Care. 2026;49(6):954-962. PMID 41296499
  13. Ekinci EI, Maldonado SG, Unseld A, et al. Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity. Diabetes Obes Metab. 2026;28(9):8242-8253. PMID 42331726
  14. Frias JP, De Block C, Brown K, et al. Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2). J Clin Endocrinol Metab. 2024;109(7):1745-1753. PMID 38252888
  15. Jun JE, Oh DH, Jeong IK, et al. Dulaglutide versus empagliflozin as add-on therapy to metformin and sulfonylurea in type 2 diabetes: a randomized pilot study with exploratory metabolomic and microbiome analyses. Front Endocrinol (Lausanne). 2026;17:1843595. PMID 42388875
  16. American Diabetes Association Professional Practice Committee for Diabetes* . 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Supplement_1):S27-S49. PMID 41358893
  17. Labcorp. Test 004333: Insulin. Methodology, specimen, patient preparation, reference range, limitations and LOINC map. labcorp.com/tests/004333/insulin
  18. Quest Diagnostics. Test 561: Insulin. Test directory: methodology, specimen, patient preparation, LOINC and risk categories. testdirectory.questdiagnostics.com/test/test-detail/561/insulin?cc=PHP
  19. Larsen PB, Linneberg A, Hansen T, et al. Reference intervals for C-peptide and insulin derived from a general adult Danish population. Clin Biochem. 2017;50(7-8):408-413. PMID 27989491
  20. Labcorp. Test 884247: NMR LipoProfile With Lipids (Without Graph). Description of the Lipoprotein Insulin Resistance Index (LP-IR). labcorp.com/tests/884247/nmr-lipoprofile-with-lipids-without-graph

Educational information, not medical advice. Lab ranges and test codes were checked on November 2, 2026. Always use the range printed on your own report, and talk to a clinician about your results.